HPV阴性头颈鳞癌的预后基因表达特征
该观察性队列研究基于欧洲BD2Decide项目数据,分析2008至2017年间接受根治性放疗的局部晚期非转移性HPV阴性头颈鳞癌患者,评估多种基因表达特征的预后价值。172基因特征在预测总生存、无病生存、无远处转移生存和无局部区域复发生存方面准确性最高,优于TNM分期系统。多变量分析证实其独立预后价值。
要点
- 172基因特征在预测OS、DFS、DMFS和LRRFS方面准确性高于TNM分期系统。
- 多变量分析证实172基因特征具有独立预后价值。
- 研究纳入783例局部晚期非转移性HPV阴性HNSCC患者,接受根治性放疗。
核心结论
- 172基因特征较TNM分期提供更优的预后信息,支持其用于HPV阴性HNSCC更好的风险分层和个体化治疗规划。
研究设计与样本
- 观察性队列研究,使用欧洲BD2Decide项目数据,系统分析2008至2017年间接受根治性放疗(术后或根治性)的局部晚期非转移性HPV阴性HNSCC患者(III-IVa/b期)的基因表达。
主要发现
- 研究纳入783例患者,中位年龄63岁,男性占68%,显著烟草暴露占84%,酒精暴露占69%。
- 172基因特征在预测OS、DFS、DMFS和LRRFS方面表现出最高预后准确性,优于TNM系统。
- 多变量分析证实172基因特征的独立预后价值。
关键数值与推荐
- 主要终点为总生存(OS),次要终点包括无病生存(DFS)、无远处转移生存(DMFS)和无局部区域复发生存(LRRFS)。
- 使用ROC曲线和Cox模型的风险比(HR)评估所选基因表达特征的预后性能。
临床怎么用
- 172基因特征可用于HPV阴性HNSCC的风险分层和个体化治疗规划。
- 未来试验应考虑肿瘤生物学和基因特征以更好地选择患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer-related deaths worldwide, with HPV-negative cases being particularly aggressive. These cases often show poor prognosis and low responsiveness to radiotherapy. Improved prognostic tools and treatment strategies are needed to enhance outcomes. AIM: To evaluate the prognostic value of various gene expression signatures in predicting survival outcomes in HPV-negative HNSCC patients receiving radiotherapy and to compare their accuracy against the current TNM staging system. METHODS: This observational cohort study used data from the European BD2Decide project, systematically analyzing gene expression in loco-regionally advanced, non-metastatic HPV-negative HNSCC patients (stage III-IVa/b) treated with curative radiotherapy (post-operative or definitive) between 2008 and 2017. The primary outcome was overall survival (OS), with secondary outcomes including disease-free survival (DFS), distant metastasis-free survival (DMFS), and loco-regional recurrence-free survival (LRRFS). The prognostic performance of selected gene expression signatures was evaluated using receiver operating characteristic (ROC) curves and hazard ratios (HR) from Cox models. RESULTS: The study included 783 patients, with a median age of 63 years, mostly male (68 %), with significant tobacco (84 %) and alcohol (69 %) exposure. The 172-gene signature (172GS) showed the highest prognostic accuracy, outperforming the TNM system in predicting OS, DFS, DMFS, and LRRFS. Multivariable analysis confirmed its independent prognostic value. CONCLUSIONS: The 172GS gene signature offers superior prognostic information compared to TNM staging, supporting its potential use for better risk stratification and personalized treatment planning in HPV-negative HNSCC. Future trials should consider tumor biology and gene signatures for better patient selection. TRIAL REGISTRATION: NCT02832102.
引用
- Cavalieri S, Brakenhoff RH, Leemans CR, et al. Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma. Radiother Oncol. 2025. PMID: 40252811. doi:10.1016/j.radonc.2025.110900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。